Put on your Buffett bib, investors, and dig into our buffet of financial treats.

Land of the Optimists

It's never too early for deep thoughts. "Truth can be elusive in the investment world, partly because no one wants you to find it," writes Tim Hanson, co-advisor of the Motley Fool Global Gains investing service. "Remember, though, that you're going to hear a lot of good stories in the stock market, so be choosy about what you invest in and know as much as you can before you jump in," advised Tim from Greece, where he traveled with two other Fool analysts.

Tim lets readers in on how he proceeds after getting to a foreign land that could be full of investing opportunities. Here's one step in the process: Talk to people with opposite points of view to find out what they know.

Investors can implement that advice in researching stocks for themselves, even if they don't get their passports stamped. Click to the story to find out more about the Crisis in Greece and how you might profit from it.

Alan Greenspan on the Financial Collapse

Before you read former Fed Chairman Alan Greenspan's 66-page letter on the causes of the financial meltdown, let Fool columnist Morgan Housel point out five great points and three ridiculous ones.

Greenspan is right about the role of Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE) in the subprime fiasco, Morgan says, and also about the failure of "too big to fail." But Greenspan goes awry when talking about the Fed's role in the housing boom and the relationship between crippling bubbles and central planning.

Says Morgan: "You can simultaneously have dynamic free markets and common-sense rules that prevent pizza delivery guys from living like they're on MTV Cribs. ... Bubbles are a natural part of human behavior. ... But it's pretty weak to just roll over and accept their wrath as inevitable."

Click to the article for Morgan's full analysis.

Health-Care Reform Passes! Here's Where to Invest Now

It's historic, it's massive, it's here. Investors want to know: What's the best way to profit from the health-care overhaul?

Fool Brian Orelli tackles that question, highlighting drugmakers (who didn't get slapped as hard as some wanted), pharmacy benefit managers and generic-drug makers (both in a sweet seat to help control costs), and insurers (who face compressed margins but have opportunities to adapt and do well).

"[H]ealth care reform should add some 30 million new faces to the ranks of the insured, all of them now better able to afford medications," Brian writes. "The biggest benefit will come for drugs that don't have an immediate effect on health," such as Merck's (NYSE: MRK) diabetes drug, Januvia, or cholesterol drugs from Pfizer (NYSE: PFE) and AstraZeneca (NYSE: AZN). People may have skipped the medicines when they had to foot the bill, but insurance coverage could change that.

Click to Brian's article for more perspective on taking advantage of the changes.

Fool online editor Kris Eddy owns no shares of any stocks mentioned in this article. Pfizer is a recommendation of Motley Fool Inside Value. Try any of our investing newsletters free for 30 days. The Fool has a disclosure policy.